Targeting GITR to treat clogged arteries
Unraveling the cell divergent roles of Glucocorticoid-Induced TNF-R Related Protein (GITR): A new opportunity to treat atherosclerosis using targeted immunotherapy
Testing whether targeting a protein called GITR can calm artery inflammation and help people with atherosclerosis reduce dangerous plaque.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11247935 on NIH RePORTER |
What this research studies
Researchers will study GITR, an immune protein found on T cells and macrophages, in human artery plaques and in mouse models to understand how it shapes plaque inflammation and stability. They will use single-cell sequencing and cell-type specific experiments to pinpoint which immune cells drive disease and how GITR signals in those cells. Based on those results, the team will test targeted immunotherapy approaches in preclinical models to see if altering GITR can change plaque behavior. The project combines human tissue analysis, advanced lab methods, and animal studies to move toward treatments that act on the immune system inside plaques.
Who could benefit from this research
Good fit: People with atherosclerosis—such as those with coronary or carotid artery plaques or undergoing vascular procedures—would be most relevant for participation or tissue donation.
Not a fit: People without artery plaque or whose heart disease is driven mainly by non-inflammatory causes may not see direct benefit from this approach.
Why it matters
Potential benefit: If successful, this could lead to new immune-based treatments that stabilize plaques and lower the risk of heart attack and stroke.
How similar studies have performed: Prior anti-inflammatory trials have reduced cardiovascular events, but directly targeting immune checkpoints like GITR is a newer approach supported mainly by promising preclinical data and little clinical testing so far.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Lutgens, Esther — Mayo Clinic Rochester
- Study coordinator: Lutgens, Esther
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.